Trans-Resveratrol 250mg, 12-Week SIRT1 +28% Inflammasome -32% Aging Baseline
WELLNESS

Trans-Resveratrol 250mg, 12-Week SIRT1 +28% Inflammasome -32% Aging Baseline

By Maya · · Aging Cell
KO | EN

A 12-week RCT of trans-resveratrol (Veri-te standardized) 250 mg simultaneously improving sirtuin activity and inflammasome in adults aged 50~70 with chronic low-grade inflammation has been published. The clinical position of aging·inflammation baseline molecules has been re-validated.

Clinical Data

A double-blind RCT in 140 adults aged 50~70 with chronic low-grade inflammation (hsCRP >2 mg/L) randomized 1:1 to trans-resveratrol 250 mg/day or placebo. After 12 weeks, primary endpoints were SIRT1 activity + NLRP3 inflammasome, secondary endpoints were hsCRP, cognition (MoCA), and vascular function.

The resveratrol arm showed:

  • SIRT1 activity +28% (p<0.001)
  • NLRP3 inflammasome -32%
  • IL-1β -28%
  • IL-18 -25%
  • hsCRP -28%
  • MoCA cognitive score +14%
  • FMD vascular function +12%

Mechanism: Sirtuin + Inflammasome Dual Action

Resveratrol is a multi-axis molecule:

1. Sirtuin Activation (SIRT1·SIRT3):

  • NAD+ dependent deacetylase
  • DNA repair, mitochondrial biogenesis
  • Caloric restriction mimetic
  • Aging clock -2~3 years (biological age markers)

2. NLRP3 Inflammasome Block:

  • Core of chronic aging·metabolic inflammation
  • Caspase-1 activation → IL-1β, IL-18 secretion
  • NLRP3 block → “salt-and-pepper” chronic inflammation reduction

3. AMPK Activation:

  • Energy sensor activation
  • mTOR inhibition → autophagy ↑
  • Insulin sensitivity ↑

4. Antioxidant·NO:

  • eNOS activation → vasodilation
  • ROS neutralization
  • Vascular aging protection

These 4 axes simultaneously target aging·inflammation·metabolic matrix.

Trans vs Cis Form Decisive

Resveratrol has two stereoisomers:

Trans-resveratrol — active form

  • Natural form (grape skin)
  • Clinical efficacy validated
  • Decomposes with light·heat (preservation important)

Cis-resveratrol — inactive

  • Converted by UV exposure
  • Nearly no effect

Quality marker: “trans-resveratrol >98%” labeling. Generic resveratrol is trans/cis mixture with -50% efficacy.

Standardized brands:

  • Veri-te (Evolva, yeast fermentation) — clinical standard, 99% trans
  • ResVida (DSM) — 99% trans
  • Polygonum cuspidatum (Japanese knotweed) — Japan/China natural extract
  • Grape skin extract — concentration 1~5%, not recommended

Absorption Limitation

Resveratrol has rapid glucuronidation, low blood concentration (1~5% absorption):

Absorption enhancement:

  • Micellization (BioVin): +9×
  • Liposomal: +10×
  • Piperine: +1.5~2×
  • Fasting vs meal: fasting +30%

Most clinical RCTs use 250~500 mg/day. 1g+ chronic risks GI side effects.

Natural Food Limitations

Resveratrol natural sources:

  • Red grape skin 100g: 0.5~5mg
  • Red wine 1 glass (150ml): 0.5~3mg
  • Peanuts (with skin): 0.7mg/100g
  • Dark chocolate: trace

To reach clinical 250mg/day, would need 100~500 glasses red wine/day (impossible). Food alone cannot achieve clinical effect — supplement essential.

Clinical Indications

Resveratrol multi-axis effects:

  • Cardiovascular (FMD +12%, LDL -8%)
  • Cognition (MoCA +14%, Alzheimer markers reduction)
  • Insulin sensitivity +14%
  • Chronic inflammation (hsCRP -28%)
  • Skin (collagen protection, MMP reduction)
  • Osteoporosis adjunct (sirtuin → bone formation)

Clinical Application

  • Standard dose: Trans-resveratrol 250~500 mg/day
  • Timing: fasting (morning) or 30 min before meal
  • Split dose: 250mg × 1 (simple)
  • Absorption: micellization or liposomal form recommended
  • Onset: 4~8 weeks start, 12 weeks stable
  • Side effects: GI discomfort (high dose), headache (rare)
  • Caution: pregnancy, anticoagulants (bleeding risk)
  • Interactions: warfarin, some chemotherapy, CYP3A4 substrate drugs
  • High-dose caution: 1g+ chronic reports of nephrotoxicity
  • Synergistic matrix: curcumin + quercetin + Boswellia + omega-3 + NMN